Whitepaper: In search of a disease-modifying agent for Parkinson’s disease: a discovery story
Posted: 21 November 2017 | Charles River Laboratories | No comments yet
Are selective, brain-penetrant inhibitors of LRRK2 an answer?
Parkinson’s disease afflicts an estimated 6.3 million people globally, and there is currently no disease-modifying therapy that halts the progression of the disease.
Genentech partnered with Charles River Laboratories to research the possibility of using leucine-rich repeat kinase 2 (LRRK2) inhibitors as therapeutic agents for the treatment of autosomal-dominant Parkinson’s disease.
This report summarises the exhaustive research process used to identify, optimise and test the safety of a compound that showed promise in inhibiting phosphorylated LRRK2 in the brain.
This whitepaper is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related content from this organisation
- bit.bio raises $103 million in first close of Series B financing
- Cell-based assays market set to exhibit CAGR of 8.5 percent
- Under the microscope: CROs and microplate reader requirements
- Charles River Laboratories continues commitment to oncology drug discovery
- Charles River to present collaborative methods at Neuroscience 2018
Related topics
Biologics, Drug Development, Drug Discovery, Kinases, LRRK2, Regenerative Medicine, Therapeutics
Related organisations
Charles River Laboratories